Activating KRAS gene mutations occur in one-third of human cancers, including adenocarcinomas of the pancreas (80%–90%), colon (45%), and lung (30%–50%),7 and also in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia,8, 9 and breast cancer.10 This evidence concerns the gene KRAS and breast carcinoma.